We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert Panel Says Benefits of BD’s Lutonix Don’t Outweigh Risks
Expert Panel Says Benefits of BD’s Lutonix Don’t Outweigh Risks
The FDA’s Circulatory Devices Advisory Committee voted 14 to 3 in a Feb. 17 meeting that the benefits of Becton Dickinson’s Lutonix 014 drug-coated balloon don’t outweigh the risks for the proposed indications for use.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor